McKesson (MCK)
(Delayed Data from NYSE)
$550.72 USD
+3.25 (0.59%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $551.01 +0.29 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$550.72 USD
+3.25 (0.59%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $551.01 +0.29 (0.05%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Why Earnings Season Could Be Great for McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Uber (UBER) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Higher ridesharing revenues are likely to have boosted Uber's (UBER) top line in fourth-quarter 2019.
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) core U.S. Pharmaceutical and Specialty Solutions unit is expected to reflect in fiscal Q3 results.
MCK vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: McKesson, Chipotle Mexican Grill, Microchip Technology, Kellogg and CDW
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McKesson, Chipotle Mexican Grill, Microchip Technology, Kellogg and CDW
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 Top Large-Cap Stocks Set to Soar on Earnings Next Week
by Nalak Das
In line with improving earnings results, six large-cap stocks are poised to beat earnings estimates next week.
The Zacks Analyst Blog Highlights: Alphabet, salesforce.com, L3Harris, McKesson and Synopsys
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, salesforce.com, L3Harris, McKesson and Synopsys
Is McKesson (MCK) a Profitable Stock for Value Investors?
by Zacks Equity Research
McKesson (MCK) is a good value-oriented pick for investors from all angles.
Buy 6 Top-Ranked Surging S&P 500 Stocks to Gain More in 2020
by Nalak Das
Several large-cap stocks within the index have already popped more than 10% year to date and still have strong upside left.
Will McKesson Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in McKesson.
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF
by Sanghamitra Saha
The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.
10 Top-Ranked S&P 500 Stocks Outperforming in 2020
by Sweta Killa
The rally has been broad based and there are winners across various corners of the space.
Is McKesson (MCK) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Zacks Analyst Blog Highlights: Estee Lauder, Bank of New York ??? Mellon, Canadian Pacific Railway, McKesson and Ameriprise Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Estee Lauder, Bank of New York ??? Mellon, Canadian Pacific Railway, McKesson and Ameriprise Financial
Top Stock Reports for Estee Lauder, BNY Mellon & Canadian Pacific Railway
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Estee Lauder (EL), Bank of New York Mellon (BK) and Canadian Pacific Railway (CP).
MCK vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
McKesson, Walgreens Form JV for European Pharmaceutical Unit
by Zacks Equity Research
The VA selects McKesson (MCK) as their prime pharmaceutical supplier.
SaMD Drives All Facets of US Healthcare: 3 Stocks to Watch
by Sreyoshi Mukherjee
As IoT slowly takes over the healthcare fraternity, let's take a look at three stocks which might prove to be profitable investment options over the long run.
Fed Reportedly Opens Criminal Investigation on Opioid Makers
by Kinjel Shah
Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.
McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat
by Zacks Equity Research
McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.